A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Gastroesophageal Junction Adenocarcinoma|HER2 Low Breast Neoplasms|HER2 Positive Breast Neoplasms|Stomach Neoplasms|Triple Negative Breast Neoplasms
Interventions: DRUG: disitamab vedotin|DRUG: tucatinib
Sponsor: Seagen Inc.
Collaborators: RemeGen Co., Ltd.